Evidence map›Paper›PMID 25352458›Full record

ReviewArquivos brasileiros de cardiologia2015

Effects of PDE type 5 inhibitors on left ventricular diastolic dysfunction in resistant hypertension.

Ana Paula Cabral de Faria, Rodrigo Modolo, Beatriz Vaz Domingues Moreno, Heitor Moreno

Open access · diamondAbstract readReview
In one paragraph

Review in Arquivos brasileiros de cardiologia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ana Paula Cabral de FariaFaculdade de Ciências Médicas, Universidade Estadual de Campinas, São Paulo, SP, Brazil.
Rodrigo ModoloFaculdade de Ciências Médicas, Universidade Estadual de Campinas, São Paulo, SP, Brazil.
Beatriz Vaz Domingues MorenoFaculdade de Ciências Médicas, Universidade Estadual de Campinas, São Paulo, SP, Brazil.
Heitor MorenoFaculdade de Ciências Médicas, Universidade Estadual de Campinas, São Paulo, SP, Brazil.
Universidade Estadual de Campinas (UNICAMP) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistant hypertension (RHTN) is a multifactorial disease characterized by blood pressure (BP) levels above goal (140/90 mmHg) in spite of the concurrent use of three or more antihypertensive drugs of different classes. Moreover, it is well known that RHTN subjects have high prevalence of left ventricular diastolic dysfunction (LVDD), which leads to increased risk of heart failure progression. This review gathers data from studies evaluating the effects of phosphodiesterase-5 (PDE-5) inhibitors (administration of acute sildenafil and short-term tadalafil) on diastolic function, biochemical and hemodynamic parameters in patients with RHTN. Acute study with sildenafil treatment found that inhibition of PDE-5 improved hemodynamic parameters and diastolic relaxation. In addition, short-term study with the use of tadalafil demonstrated improvement of LVDD, cGMP and BNP-32 levels, regardless of BP reduction. No endothelial function changes were observed in the studies. The findings of acute and short-term studies revealed potential therapeutic effects of IPDE-5 drugs on LVDD in RHTN patients.

Indexed as

CarbolinesDiastoleDrug ResistanceHeart Failure, DiastolicHumansHypertensionMedical IllustrationPhosphodiesterase 5 InhibitorsPiperazinesPurinesSildenafil CitrateSulfonamidesTadalafilTreatment OutcomeVentricular Dysfunction, LeftCarbolinesPhosphodiesterase 5 InhibitorsPiperazinesPurinesSildenafil CitrateSulfonamidesTadalafil

Identifiers

PMID25352458
PMCPMC4387615
OpenAlexW2136093305

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.